Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...

Tumor-agnostic therapies in a high-volume Brazilian center: Real-world challenges and opportunities. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

In a phase 1 study, an erdafitinib intravesical drug-releasing system showed preliminary safety as well as efficacy in NMIBC with FGFR alterations. TAR-210, an erdafitinib intravesical drug-releasing ...

A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a ...

Further studies should be conducted, particularly in bladder cancer where about 35% of patients are FGFR mRNA positive." Commenting on the results, Prof Giuseppe Curigliano, Chair of the Division of ...

FGFR alterations are common in early-stage bladder cancer, occurring in approximately 70 percent of intermediate-risk and 40 percent of high-risk non–muscle-invasive bladder cancer tumors. 2,3 Because ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the ...

RARITAN, N.J., March 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical ...